RT Journal Article
SR Electronic
T1 Association between SSRI Antidepressant Use and Reduced Risk of Intubation or Death in Hospitalized Patients with Coronavirus Disease 2019: a Multicenter Retrospective Observational Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.09.20143339
DO 10.1101/2020.07.09.20143339
A1 Hoertel, Nicolas
A1 Rico, Marina Sánchez
A1 Vernet, Raphaël
A1 Beeker, Nathanaël
A1 Jannot, Anne-Sophie
A1 Neuraz, Antoine
A1 Salamanca, Elisa
A1 Paris, Nicolas
A1 Daniel, Christel
A1 Gramfort, Alexandre
A1 Lemaitre, Guillaume
A1 Bernaux, Mélodie
A1 Bellamine, Ali
A1 Lemogne, Cédric
A1 Airagnes, Guillaume
A1 Burgun, Anita
A1 Limosin, Frédéric
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/08/07/2020.07.09.20143339.abstract
AB Objective To examine the association between antidepressant use and the risk of intubation or death in hospitalized patients with COVID-19.Design Multicenter observational retrospective cohort study.Setting Greater Paris University hospitals, France.Participants 7,345 adults hospitalized with COVID-19 between 24 January and 1 April 2020, including 460 patients (6.3%) who received an antidepressant during the visit.Data source Assistance Publique-Hôpitaux de Paris Health Data Warehouse.Main outcome measures The primary endpoint was a composite of intubation or death. We compared this endpoint between patients who received antidepressants and those who did not in time-to-event analyses adjusting for patient characteristics (such as age, sex, and comorbidities), disease severity and other psychotropic medications. The primary analyses were multivariable Cox models with inverse probability weighting.Results Over a mean follow-up of 18.5 days (SD=27.1), 1,331 patients (18.1%) had a primary end-point event. Unadjusted hazard ratio estimates of the association between antidepressant use and the primary outcome stratified by age (i.e., 18-50, 51-70, 71-80, and 81+) were non-significant (all p>0.072), except in the group of patients aged 71-80 years (HR, 0.66; 95% CI, 0.45 to 0.98; p=0.041). Following adjustments, the primary analyses showed a significant association between use of any antidepressant (HR, 0.64; 95% CI, 0.51 to 0.80; p<0.001), SSRI (HR, 0.56; 95% CI, 0.42 to 0.75; p<0.001), and SNRI (HR, 0.57; 95% CI, 0.34 to 0.96; p=0.034), and reduced risk of intubation or death. Specifically, exposures to escitalopram, fluoxetine, and venlafaxine were significantly associated with lower risk of intubation or death (all p<0.05). These associations remain significant in multiple sensitivity analyses, except for the association between SNRI use and the outcome.Conclusions SSRI use could be associated with lower risk of death or intubation in hospitalized patients with COVID-19. Double-blind controlled randomized clinical trials of these medications for COVID-19 are needed.What is already known on this topicA prior meta-analysis, mainly including studies on selective serotonin reuptake inhibitors (SSRIs), showed that antidepressant use in major depressive disorder was associated with reduced levels of several pro-inflammatory cytokines, including IL-6, TNF-α, and CCL-2, which have been suggested to be associated with severe COVID-19.A recent in-vitro study supports antiviral effects of the SSRI fluoxetine on SARS-CoV-2.To our knowledge, no study has examined the efficacy of antidepressants in patients with COVID-19.What this study addsIn a multicenter observational retrospective study, we examined the association between antidepressant use and the risk of intubation or death in hospitalized patients with COVID-19, adjusting for patient characteristics, disease severity and other psychotropic medications.Antidepressant use was significantly and substantially associated with reduced risk of intubation or death.At the level of antidepressant classes, SSRI use was significantly and substantially associated with reduced risk of intubation or death, but not other antidepressant classes.At the level of antidepressant medications, exposures to the SSRIs fluoxetine and escitalopram, and the SNRI venlafaxine were significantly associated with lower risk of intubation or death.Double-blind controlled randomized clinical trials of these medications for COVID-19 are needed.Competing Interest StatementThis work did not receive any external funding. NH has received personal fees and non-financial support from Lundbeck, outside the submitted work. FL has received speaker and consulting fees from Janssen-Cilag, Eutherapie-Servier, and Lundbeck, outside the submitted work. CL reports personal fees and non-financial support from Janssen-Cilag, Lundbeck, Otsuka Pharmaceutical, and Boehringer Ingelheim, outside the submitted work. GA reports personal fees from Pfizer, Pierre Fabre and Lundbeck, outside the submitted work. Other authors declare no competing interests.Clinical TrialNAFunding StatementThis work did not receive any external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This observational study using routinely collected data received approval from the Institutional Review Board of the AP-HP clinical data warehouse (decision CSE-20-20_COVID19, IRB00011591). AP-HP clinical Data Warehouse initiative ensures patients' information and informed consent regarding the different approved studies through a transparency portal in accordance with European Regulation on data protection and authorization number 1980120 from National Commission for Information Technology and Civil Liberties (CNIL). All procedures related to this work adhered to the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from the AP-HP Health Data Warehouse can be obtained at https://eds.aphp.fr//. https://eds.aphp.fr//.